Table 4.
Univariate and multivariate analysis of DFS in ER + breast cancer patients.
| Variable | Univariate | multivariate | Hazard ratio (95% CI) |
|---|---|---|---|
| P value | P value | ||
| Age (> 35 vs. ≤ 35) | 0.639 | ||
| Menopausal status (Post vs. Pre) | 0.180 | ||
| Tumor size (≤ 2 vs. > 2 cm) | 0.031 | 0.078 | 2.031 (0.923, 4.471) |
| Lymph node metastasis (Yes vs. No) | 0.001 | 0.001 | 4.079 (1.741, 9.558) |
| Vascular invasion (Yes vs. No) | 0.049 | 0.040 | 3.603 (1.061, 12.235) |
| Histological grade (III vs. I–II) | 0.116 | ||
| PR status (Positive vs. Negative) | 0.017 | 0.015 | 0.346 (0.147, 0.813) |
| Ki-67 (≥ 14% vs. < 14%) | 0.319 | ||
| HER-2 status (Positive vs. Negative) | 0.367 | ||
| SLCO1B3 expression (Positive vs. Negative) | 0.352 | ||
| Chemotherapy (Yes vs. No) | 0.611 | ||
| Endocrine therapy (Yes vs. No) | 0.737 |
P values less than 0.05 are considered as significant changes.